- In April 2023, Thermo Fisher Scientific Inc. launched a next-generation ELISA kit platform designed to deliver higher sensitivity and faster results for both research and clinical applications. These kits feature advanced signal detection technologies, reducing assay times and improving reproducibility across a range of biomarker analyses. This innovation reflects Thermo Fisher’s strategic focus on accelerating diagnostic accuracy and efficiency in laboratories worldwide
- In March 2023, Bio-Techne Corporation announced the expansion of its automated ELISA product line under the brand Ella, integrating it with the Simple Plex platform. This development offers high-throughput and fully automated solutions for immunoassay workflows, meeting the growing demand for precision diagnostics in oncology, inflammation, and neurology. The company’s commitment to lab automation and simplified workflows positions it strongly in the competitive ELISA market
- In February 2023, Merck KGaA (Germany), through its life science division MilliporeSigma, introduced multiplex ELISA kits tailored for cytokine and chemokine detection in preclinical studies. These kits support simultaneous quantification of multiple analytes, enhancing data richness and assay efficiency. The product line strengthens Merck’s diagnostic and life sciences portfolio, aligning with trends in biomarker discovery and translational research
- In February 2023, Abcam plc expanded its ELISA portfolio by launching a new line of recombinant monoclonal antibody-based ELISA kits. These kits offer improved specificity and consistency, tailored to applications in cancer and autoimmune disease research. This launch reinforces Abcam’s emphasis on reproducibility and quality assurance in life science research tools, meeting evolving academic and biopharmaceutical research needs.
- In January 2023, Enzo Life Sciences unveiled a novel colorimetric ELISA platform for the detection of oxidative stress markers, targeting cardiovascular and metabolic research applications. The kits are designed for easy integration into standard lab workflows and address the growing need for affordable, reliable tools in chronic disease research. Enzo’s continued innovation in niche diagnostic segments highlights its strategic expansion into specialty assay market
